Commission regulation uncertainty
Yashish stated media has more visibility than regulators on this topic, though he acknowledged two regulatory conversations (deferred revenues in life, lower EOM in health) that they would 'welcome.'
POLICYBZR / Q4-FY26 / risks
Keep the risk register visible.
PB Fintech · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Sustainability of 60%+ health growth
Sarbvir deflected when asked for specific guidance on next year, stating focus should be on fundamentals rather than speculating on growth rates. Yashish then gave bullish commentary but without specific numbers.
PB Health capital raise dilution
Manas asked specifically whether PB Fintech would participate in the next funding round. Yashish gave non-committal response: 'When it comes to the board, yeah, PB Fintech might consider it.' This represents potential cash outflow or strategic uncertainty.
Revenue recognition receivable timing
Sanketh asked for split of INR 6,794 crore revenue between recognized-received vs recognized-receivable. Management deflected saying they could explain 'in a more closed setting,' suggesting this is material information not disclosed publicly.